Navigation Links
Arteriocyte and the U.S. Army Institute of Surgical Research (USAISR) Sign a CRADA to Speed Development of Cellular Therapies for Orthopaedic Trauma
Date:6/7/2011

CLEVELAND, June 7, 2011 /PRNewswire-USNewswire/ -- Arteriocyte™, a leading clinical stage biotechnology company with offices in Cleveland, Ohio, and Hopkinton, Massachusetts, that develops proprietary stem cell and tissue engineering based therapies, announced today that they have entered into a Cooperative Research and Development Agreement (CRADA) with the United States Army Institute of Surgical Research (USAISR) at Fort Sam Houston, Texas. The 3-year CRADA, entitled "The Use of Concentrated Bone Marrow Aspirate from a Point-of-Care Device in Orthopaedic Trauma," enables collaborative investigation of new stem cell based therapies for orthopaedic trauma and related battlefield injuries using Arteriocyte's Magellan MAR01™ system for rapid bed-side production of cellular therapies and Arteriocyte's NANEX™ rapid stem cell expansion technology.

(Logo: http://photos.prnewswire.com/prnh/20100624/ALOGO)

Arteriocyte is currently working with USAISR to evaluate Magellan® point-of-care therapies for compartment syndrome (amputation prevention), burn debridement, and post-surgical wound infection prevention under existing research agreements. The newly established CRADA will enable Arteriocyte to work directly with USAISR staff to explore broader use of its technologies to treat orthopaedic trauma including limb injuries (bone, cartilage, muscle and vessel structure) that affect a majority of battlefield wounded soldiers.

Joseph Wenke, Ph.D., Manager, Extremity Trauma and Regenerative Medicine Task Area, and Manager, Orthopaedic Extremity Trauma Research Program, will serve as Principal Investigator for USAISR. "We're excited to expand our collaboration with Arteriocyte," said Dr. Wenke. "Rapid development and deployment of improved treatments for Orthopaedic Trauma is central to USAISR's mission.  These technologies have significant potential to improve outcomes for our injured personnel, and assist in their healthy recovery to active duty."

The Magellan® system is an FDA 510(k) cleared medical device for the rapid production of platelet rich plasma from blood and bone marrow that is applied to a surgical site as surgeons deem necessary for their clinical use requirements. Magellan MAR01™ technology enables the rapid "closed system" concentration of aspirated bone marrow, yielding an injectable tissue rich in platelets, hematopoietic stem cells and mesenchymal stem cells, commonly viewed as key components in tissue repair. The self contained Magellan unit provides critical ease-of-use and operator-independent consistency necessary for deployment in military medical operations. In addition to therapies for battlefield wounds, Arteriocyte is currently enrolling patients into an FDA approved Phase I IDE clinical trial to evaluate the role of MAR01™ in peripheral vascular disease (critical limb ischemia) with additional cardiac and orthopedic trials planned.

The NANEX™ platform consists of a biofunctional nanofiber-based 3D scaffold designed to mimic the bone marrow environment, permitting rapid ex vivo proliferation of hematopoietic stem cells with minimal differentiation. Arteriocyte has multiple active development programs for its NANEX technology including treatment of ischemic disease, identification and treatment of cancers of the blood system and rapid high volume ex vivo red blood cell production.

Arteriocyte CEO Don Brown said, "We consider it a privilege to be requested by the U.S. Military to help in the care delivery for our men and women in uniform. We strongly believe it is our responsibility to make Arteriocyte's technologies available to those who volunteer to serve our country, and we are humbled by the opportunity to work with our partners at Fort Sam Houston to help ensure that our wounded soldiers get access to the best care possible so they can get home or back to active duty as quickly as possible."

About Arteriocyte

Arteriocyte, a leading clinical stage biotechnology company, is dedicated in developing novel stem cell products and medical devices for unmet clinical needs. Arteriocyte leverages its expertise in stem cell and tissue engineering in order to develop a broad portfolio of cell based therapeutics to improve patient outcomes. In October of 2007, Arteriocyte partnered with DW Healthcare Partners and Comerica to create Arteriocyte Medical Systems Inc., in order to commercialize and distribute novel medical devices and point of care surgical solutions to address serious unmet medical needs in cardiac, orthopedic and vascular surgeries. Arteriocyte Medical Systems manufactures and distributes the Magellan® Autologous Platelet Separator System.


'/>"/>
SOURCE Arteriocyte, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Arteriocyte Receives FDA Approval to Move Forward with Critical Limb Ischemia Trial
2. Arteriocyte Named Top Biotech Start Up Venture by the Ohio Venture Association for 2010
3. Ontario Institute for Cancer Research Announces Spin Off Companies Developing Promising Anticancer Technologies
4. Ludwig Institute for Cancer Research and Polaris Group Form Collaboration to Expand Development of Polaris Novel Cancer Drug, ADI-PEG 20
5. Northwest Biotherapeutics and the Fraunhofer Institute for Cell Therapy and Immunology are Partnering for Clinical Trials and Compassionate Use Cases in Europe
6. Larta Institute Receives Award for National Institutes of Health Commercialization Assistance Program at 2011 Acquisition, Grants, and Small Business Symposium
7. Van Andel Institute Earns Highest "Green Building" Award
8. LifeNet Health Breaks Ground on New Institute of Regenerative Medicine
9. The Wound Institute® to Feature Educational Forum on Dynamic Reciprocity During the Symposium on Advanced Wound Care and the Wound Healing Society Annual Meeting
10. MabVax Therapeutics Receives $1.8 Million in a Phase 2 Small Business Innovation Research Program Award From the National Cancer Institute
11. IBM and The Institute of Bioengineering and Nanotechnology Find Breakthrough for MRSA Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2017)... , ... June 22, 2017 , ... ... leaders in designating infertility as a disease, bringing new hope for prospective parents ... their 2017 annual meeting to back the World Health Organization’s designation in hopes ...
(Date:6/22/2017)... ... June 22, 2017 , ... Tunnell ... the biopharma and life sciences industries, continue to be in demand for their ... Wolf will be speaking on “The State of Information Governance in the Biopharmaceutical ...
(Date:6/22/2017)... ... June 22, 2017 , ... RURO, Inc., ... Limfinity® version 6.5, a content-packed update to the Limfinity® framework. , LimitLIS® and ... and more diverse base of customers among labs and other businesses. Limfinity® 6.5 ...
(Date:6/20/2017)... ... June 20, 2017 , ... ... CTNext board of directors has formed a Higher Education Entrepreneurship Advisory Committee to ... of institution presidents and other high-ranking representatives from 35 higher education institutions across ...
Breaking Biology Technology:
(Date:4/13/2017)... 13, 2017 According to a new market research ... Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and ... is expected to grow from USD 14.30 Billion in 2017 to USD ... 17.3%. ... MarketsandMarkets Logo ...
(Date:4/6/2017)... Forecasts by Product Type (EAC), ... End-Use (Transportation & Logistics, Government & Public Sector, Utilities ... Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), ... you looking for a definitive report on the $27.9bn ... ...
(Date:4/3/2017)...  Data captured by IsoCode, IsoPlexis Corporation,s ... statistically significant association between the potency of ... objective response of cancer patients post-treatment. The ... cancer patients will respond to CAR-T cell ... to improve both pre-infusion potency testing and cell ...
Breaking Biology News(10 mins):